Bluejay Diagnostics, Inc.
corporate_fare Company Profile
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 40 items for BJDX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for BJDX spans 10-Q, 8-K, 424B3, S-3.
Recent high-impact activity:
- Bluejay Q3: $7.4M Cash, Going Concern Reaffirmed, $10-14M Raise Still Needed
- Bluejay Sets 1-for-4 Reverse Split Effective November 3 to Shore Up Nasdaq Listing
- Bluejay Diagnostics Completes SYMON-II Enrollment, Reports $9.6M Cash
- Bluejay Completes SYMON-II Enrollment, Cash Runway Extended to Q2 2027
- Bluejay Diagnostics Extends Cash Runway to Q2 2027, Reports $4.2M Net Loss
Financial Snapshot
Short Interest & Short Volume
1.01 days to coverFINRA reported short interest of 77,889 shares in BJDX as of the October 30, 2026 settlement, a 46.1% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 13, 2026, 61.1% of BJDX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for BJDX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-26.
Massive Share Registration for Resale · Extreme Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →